Univariate analysis of prognostic factors for progression-free and overall survival at the time of starting treatment with tafasitamab / lenalidomide in the efficacy cohort
| Cohorts . | Median PFS (95%CI) . | Median OS (95%CI) . | ||
|---|---|---|---|---|
| ITT (n=99) . | Efficacy (n=83) . | . | . | |
| Age: | P=0.94 | P=0.83 | P=0.98 | P=0.76 |
| 18-60 | 3.7 (0-19.4) | 19.6 (0-51.1) | 19.6 (0-43.1) | 19.6 (NA) |
| > 60 years | 4.9 (1.2-8.5) | 10.9 (5.7-16.1) | 11.7 (2.2-21.1) | 21.8 (7.4-36.2) |
| Double-hit HGL: | P=0.009 | P<0.001 | P=0.008 | P=0.002 |
| Yes | 1.1 (0-3.4) | 2.9 (0.6.8) | 1.3 (0-3.4) | 2.9 (0-6.4) |
| No | 6.3 (1.6-11) | 11.4 (1.3-21.5) | 15.9 (6.5-25.4) | 21.8 (NA) |
| ECOG PS: | P<0.001 | P=0.007 | P<0.001 | P=0.01 |
| 0-1 | 13.1 (1.7-24.4) | 19.1 (9-29.2) | 26.4 (NA) | 26.4 (NA) |
| 2-4 | 2.4 (0.9-3.9) | 4.7 (2.5-6.9) | 3.3 (0-8) | 7.4 (5.9-9) |
| AA stage: | P=0.23 | P=0.4 | P=0.031 | P=0.095 |
| I-II | 11 (4.1-17.9) | 13.1 (2-24.1) | NR | NR |
| III-IV | 4 (2.7-5.3) | 6.4 (0-13.5) | 8.8 (3.9-13.8) | 12.2 (1.1-23.4) |
| LDH: | P=0.004 | P=0.025 | P<0.001 | P=0.019 |
| Normal | 18.7 (4.5-32.9) | 19.6 (7.6-31.6) | NR | NR |
| Elevated | 3.6 (2.2-5) | 5.6 (3-8.1) | 5.1 (0.8-9.3) | 10.9 (4.9-16.8) |
| R-IPI: | P=0.010 | P=0.17 | P<0.001 | P=0.016 |
| 0-2 | 13.1 (0-27.2) | 18.7 (9.5-27.9) | NR | NR |
| 3-5 | 3.6 (2.5-4.6) | 6.3 (0.7-11.9) | 6.4 (3-9.7) | 11.2 (5.8-16.6) |
| CIRS: | P=0.39 | P=0.2 | P=0.99 | P=0.52 |
| 0-6 | 4 (3.2-4.8) | 4.7 (1.8-7.5) | 10.9 (5.2-16.5) | 12.2 (0-24.5) |
| >6 | 8.3 (0.3-16.3) | 19.6 (8.3-30.9) | 15.9 (2.5-29.4) | 19.6 (6.7-32.5) |
| Previous lines: | P=0.056 | P=0.21 | P=0.028 | P=0.19 |
| 1 | 11 (0.2-21.9) | 13.1 (0-27.6) | NR | NR |
| >1 | 4.3 (2.2-6.3) | 2.3 (3.5-12.6) | 9.5 (4.4-14.6) | 15.9 (6.8-25.1) |
| Previous lines: | P=0.038 | P=0.053 | P=0.25 | P=0.53 |
| 1-2 | 6.4 (0-14.3) | 19.1 (4.6-33.7) | 15.9 (2.5-29.4) | 26.4 (NA) |
| >2 | 4 (3.1-4.9) | 5.6 (1.9-9.3) | 7.4 (1-13.9) | 18.8 (3.2-34.3) |
| Previous CAR-T: | P=0.37 | P=0.28 | P=0.97 | P=0.93 |
| Yes | 2.9 (0-5.9) | 4.3 (0.5-21.6) | 5.2 (NA) | NR |
| No | 5.6 (1.7-9.5) | 11 (1.3-7.2) | 12.2 (3.1-21.4) | 21.8 (8.4-35.2) |
| Previous line response: | P=0.002 | P=0.018 | P<0.001 | P<0.001 |
| Relapse | 18.7 (8.1-29.2) | 19.6 (10.6-28.5) | NR | NR |
| Refractory/progression | 3.1 (2.4-3.7) | 4.3 (1.3-7.2) | 6.5 (2.2-10.8) | 9.5 (4.3-14.7) |
| Primary refractory: | P=0.021 | P=0.19 | P=0.005 | P=0.1 |
| Yes | 3.6 (2.6-4.6) | 5.6 (0-13.6) | 6.8 (1.5-12.1) | 12.2 (3.3-21.2) |
| No | 12 (0-27.5) | 22.2 (3.1-41.4) | NR | NR |
| Cohorts . | Median PFS (95%CI) . | Median OS (95%CI) . | ||
|---|---|---|---|---|
| ITT (n=99) . | Efficacy (n=83) . | . | . | |
| Age: | P=0.94 | P=0.83 | P=0.98 | P=0.76 |
| 18-60 | 3.7 (0-19.4) | 19.6 (0-51.1) | 19.6 (0-43.1) | 19.6 (NA) |
| > 60 years | 4.9 (1.2-8.5) | 10.9 (5.7-16.1) | 11.7 (2.2-21.1) | 21.8 (7.4-36.2) |
| Double-hit HGL: | P=0.009 | P<0.001 | P=0.008 | P=0.002 |
| Yes | 1.1 (0-3.4) | 2.9 (0.6.8) | 1.3 (0-3.4) | 2.9 (0-6.4) |
| No | 6.3 (1.6-11) | 11.4 (1.3-21.5) | 15.9 (6.5-25.4) | 21.8 (NA) |
| ECOG PS: | P<0.001 | P=0.007 | P<0.001 | P=0.01 |
| 0-1 | 13.1 (1.7-24.4) | 19.1 (9-29.2) | 26.4 (NA) | 26.4 (NA) |
| 2-4 | 2.4 (0.9-3.9) | 4.7 (2.5-6.9) | 3.3 (0-8) | 7.4 (5.9-9) |
| AA stage: | P=0.23 | P=0.4 | P=0.031 | P=0.095 |
| I-II | 11 (4.1-17.9) | 13.1 (2-24.1) | NR | NR |
| III-IV | 4 (2.7-5.3) | 6.4 (0-13.5) | 8.8 (3.9-13.8) | 12.2 (1.1-23.4) |
| LDH: | P=0.004 | P=0.025 | P<0.001 | P=0.019 |
| Normal | 18.7 (4.5-32.9) | 19.6 (7.6-31.6) | NR | NR |
| Elevated | 3.6 (2.2-5) | 5.6 (3-8.1) | 5.1 (0.8-9.3) | 10.9 (4.9-16.8) |
| R-IPI: | P=0.010 | P=0.17 | P<0.001 | P=0.016 |
| 0-2 | 13.1 (0-27.2) | 18.7 (9.5-27.9) | NR | NR |
| 3-5 | 3.6 (2.5-4.6) | 6.3 (0.7-11.9) | 6.4 (3-9.7) | 11.2 (5.8-16.6) |
| CIRS: | P=0.39 | P=0.2 | P=0.99 | P=0.52 |
| 0-6 | 4 (3.2-4.8) | 4.7 (1.8-7.5) | 10.9 (5.2-16.5) | 12.2 (0-24.5) |
| >6 | 8.3 (0.3-16.3) | 19.6 (8.3-30.9) | 15.9 (2.5-29.4) | 19.6 (6.7-32.5) |
| Previous lines: | P=0.056 | P=0.21 | P=0.028 | P=0.19 |
| 1 | 11 (0.2-21.9) | 13.1 (0-27.6) | NR | NR |
| >1 | 4.3 (2.2-6.3) | 2.3 (3.5-12.6) | 9.5 (4.4-14.6) | 15.9 (6.8-25.1) |
| Previous lines: | P=0.038 | P=0.053 | P=0.25 | P=0.53 |
| 1-2 | 6.4 (0-14.3) | 19.1 (4.6-33.7) | 15.9 (2.5-29.4) | 26.4 (NA) |
| >2 | 4 (3.1-4.9) | 5.6 (1.9-9.3) | 7.4 (1-13.9) | 18.8 (3.2-34.3) |
| Previous CAR-T: | P=0.37 | P=0.28 | P=0.97 | P=0.93 |
| Yes | 2.9 (0-5.9) | 4.3 (0.5-21.6) | 5.2 (NA) | NR |
| No | 5.6 (1.7-9.5) | 11 (1.3-7.2) | 12.2 (3.1-21.4) | 21.8 (8.4-35.2) |
| Previous line response: | P=0.002 | P=0.018 | P<0.001 | P<0.001 |
| Relapse | 18.7 (8.1-29.2) | 19.6 (10.6-28.5) | NR | NR |
| Refractory/progression | 3.1 (2.4-3.7) | 4.3 (1.3-7.2) | 6.5 (2.2-10.8) | 9.5 (4.3-14.7) |
| Primary refractory: | P=0.021 | P=0.19 | P=0.005 | P=0.1 |
| Yes | 3.6 (2.6-4.6) | 5.6 (0-13.6) | 6.8 (1.5-12.1) | 12.2 (3.3-21.2) |
| No | 12 (0-27.5) | 22.2 (3.1-41.4) | NR | NR |
Abbreviations: PFS: progression-free survival; OS: overall survival; 95%CI: 95% confidence interval; HGL: high-grade lymphoma; ECOG: Eastern cooperative oncology group; PS: performance status; AA: Ann Arbor; LDH: lactate dehydrogenase; R-IPI: revised International Prognostic Index; CIRS: cumulative illness rating scale; RDI: relative dose-intensity; T/L: tafasitamab lenalidomide; CR: complete response; PR: partial response; SD: stable disease; PD: progressive diasese; NE: not evaluable; HR: hazard ratio.